Literature DB >> 20041866

Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation.

J V Unadkat1, S Schneeberger, E H Horibe, C Goldbach, M G Solari, K M Washington, V S Gorantla, G M Cooper, A W Thomson, W P Andrew Lee.   

Abstract

Transplant vasculopathy has not been systematically investigated in composite tissue allotransplantation (CTA). The impact of multiple acute rejections (ARs) on long-term graft outcomes in reconstructive transplantation remains unknown. This study in a rat hind-limb allotransplantation model systematically analyzes vasculopathy and tissue-specific pathological changes secondary to multiple AR episodes. LEW rats were transplanted with BN rat hind limbs and treated as follows: Group 1 (Iso): isografts. Group 2 (CsA): Cyclosporine (CsA) qd; Group 3 (mult AR): CsA and dexamethasone only when AR was observed. No AR was observed in Groups 1 and 2. Multiple AR were observed in Group 3, and each episode was completely reversed (clinically) with pulsed CsA + dexamethasone treatment. Group 3 animals demonstrated significant vascular lesions along with skin and muscle atrophy, upregulation of profibrotic gene expression and fibrosis when compared to Groups 1 and 2. In addition, allograft bone was sclerotic, weak and prone to malunion and nonunion. Interestingly, vasculopathy was a late finding, whereas muscle atrophy with macrophage infiltration was seen early, after only a few AR episodes. Taken together, multiple AR episodes lead to vasculopathy and tissue-specific pathology in CTA. This is the first evidence of 'composite tissue vasculopathy and degeneration (CTVD)' in CTA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20041866     DOI: 10.1111/j.1600-6143.2009.02941.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  16 in total

1.  Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.

Authors:  L Qin; G Li; N Kirkiles-Smith; P Clark; C Fang; Y Wang; Z-X Yu; D Devore; G Tellides; J S Pober; D Jane-Wit
Journal:  Am J Transplant       Date:  2016-06-14       Impact factor: 8.086

2.  Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity.

Authors:  Raman Venkataramanan; Alexander M Spiess; Firuz G Feturi; Jignesh V Unadkat; Wensheng Zhang; Mohamed El Hag; Yong Wang; Chiaki Komatsu; Damian Grybowski; Zhaoxiang Zhang; Vasil Erbas; Huseyin Sahin; Sean Mcclaine; Sinan Oksuz; Jan Plock; Vijay S Gorantla; Kia M Washington; Mario G Solari
Journal:  Pharm Res       Date:  2022-08-02       Impact factor: 4.580

Review 3.  Vascularized composite tissue allotransplantation--state of the art.

Authors:  J Rodrigo Diaz-Siso; Ericka M Bueno; Geoffroy C Sisk; Francisco M Marty; Bohdan Pomahac; Stefan G Tullius
Journal:  Clin Transplant       Date:  2013-04-14       Impact factor: 2.863

Review 4.  Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius
Journal:  Transpl Int       Date:  2015-09-14       Impact factor: 3.782

5.  Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation.

Authors:  James D Fisher; Stephen C Balmert; Wensheng Zhang; Riccardo Schweizer; Jonas T Schnider; Chiaki Komatsu; Liwei Dong; Vasil E Erbas; Jignesh V Unadkat; Ali Mübin Aral; Abhinav P Acharya; Yalcin Kulahci; Heth R Turnquist; Angus W Thomson; Mario G Solari; Vijay S Gorantla; Steven R Little
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

Review 6.  Composite tissue allotransplantation: opportunities and challenges.

Authors:  Jasper Iske; Yeqi Nian; Ryoichi Maenosono; Max Maurer; Igor M Sauer; Stefan G Tullius
Journal:  Cell Mol Immunol       Date:  2019-03-06       Impact factor: 11.530

7.  Cutaneous leukocyte lineages in tolerant large animal and immunosuppressed clinical vascularized composite allograft recipients.

Authors:  David A Leonard; Harrison R Powell; Matthew W Defazio; Kumaran Shanmugarajah; Melissa Mastroianni; Ivy A Rosales; Evan A Farkash; Robert B Colvin; Mark A Randolph; David H Sachs; Josef M Kurtz; Curtis L Cetrulo
Journal:  Am J Transplant       Date:  2020-08-29       Impact factor: 8.086

Review 8.  Mechanisms and mediators of inflammation: potential models for skin rejection and targeted therapy in vascularized composite allotransplantation.

Authors:  Theresa Hautz; Dolores Wolfram; Johanna Grahammer; Ravi Starzl; Christoph Krapf; Johann Pratschke; W P Andrew Lee; Gerald Brandacher; Stefan Schneeberger
Journal:  Clin Dev Immunol       Date:  2012-09-19

Review 9.  The need for inducing tolerance in vascularized composite allotransplantation.

Authors:  Kadiyala V Ravindra; Hong Xu; Larry D Bozulic; David D Song; Suzanne T Ildstad
Journal:  Clin Dev Immunol       Date:  2012-10-31

Review 10.  Split rejection in vascularized composite allotransplantation.

Authors:  Indranil Sinha; Bohdan Pomahac
Journal:  Eplasty       Date:  2013-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.